|
|
|
|
Generic Names of Some Trade Name Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs -~ Generic Names of Some Trade Name Drugs - Generic Names of Some...
|
|
|
Some Trade Names of Generic Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs-~ Generic Names of Some Trade Name Drugs - Some Trade Names of...
|
|
|
Obesity: Merck Manual Home Edition
Search Recent Searches Index Sections A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Accidents and Injuries Blood Disorders Bone, Joint, and Muscle Disorders Brain, Spinal Cord, and Nerve Disorders Cancer Children's Health Issues Digestive Disorders Disorders of Nutrition and Metabolism Drugs Ear, Nose, and Throat Disorders Eye Disorders Fundamentals Heart and Blood Vessel...
|
|
|
THE MERCK MANUAL OF GERIATRICS, App. III, Trade Names of Some Commonly Used Drugs, Nabumetone to Oxytocin
Trade Names of Some Commonly Used Drugs GENERIC AND TRADE NAMES OF COMMONLY USED DRUGS Nabumetone to Oxytocin Generic Trade Name Nabumetone RELAFEN Nadolol CORGARD Nafcillin UNIPEN Na lbuphine NUBAIN Nalidixic acid NegGRAM Naloxone NARCAN Naltrexone REVIA Nandrolone DURABOLIN Naproxen ALEVE, ANAPROX, NAPROSYN Naratriptan AMERGE Nedocromil TILADE Nefazodone SERZONE Nelfinavir VIRACEPT...
|
|
|
Liposculpture and Liposuction Information - Obesity & Weight Loss
Orlistat (Xenical) The next class (category) of drugs changes the metabolism of fat.
Orlistat (Xenical) is the only drug of this category that is FDA approved.
By inhibiting the action of lipase enzymes, Xenical prevents the intestinal absorption of fat by 30%.
Theoretically, Xenical also should have minimal or no systemic side effects ...
author: Administrator
|
|
|
Orlistat for obesity - [Medication] - Quest Diagnostics Patient Health Library
Orlistat for obesity Examples Brand Name Chemical Name Xenical orlistat How It Works Orlistat prevents your intestines from absorbing some of the fat from the food you eat.
However, the unpleasant side effects of orlistat increase with the amount of fat a person eats; research shows that people taking orlistat may want to eat less fat than...
|
|
|
http://www.clbc.cam.ac.uk/Sethi/PDFS/2000_IDrugsW_Sethi.pdf page 2
duplicates:
http://www.clbc.cam.ac.uk/Sethi/SethiPDFS/IDWIBCP27_30.PDF
|
|
|
Microsoft Word - RPSepicPOM page 46
|
|
|
Prescription Drug Information
(You will be leaving the UMHS site to enter the MEDLINEplus site.) To browse by first letter of generic or brand name drug: A - Am An - Az B C - Ch Ci - Cz D - Dh Di - Dz E F G H I - J K - L M - Mh Mi - Mz N - Nh Ni - Nz O P - Pl Pm - Pz Q - R S - Sn So - Sz T - To Tp - Tz U - V W - Z 0 - 9 - UMHS provides additional drug information on these topics: Anticoagulant - Coumadin/Warfarin...
|
|
|
Analytical CRM new technologies for the pharmaceutical industry
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
author: BioPortfolio - Knowledge Management, Market Analysis and Market Research
|
|
|
Analytical CRM: new technologies for the pharmaceutical industry
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
author: BioPortfolio - Knowledge Management, Market Analysis and Market Research
|
|
|
JNK1 as a promising target for obesity, diabetes and insulin resistance
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
|
|
|
JNK1 as a promising target for obesity, diabetes and insulin resistance
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
|
|
|
Failure of eating to trigger ghrelin reduction in obesity
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
|
|
|
LeadDiscovery
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
|
|
|
http://www.biosis.org/ts/media/cdjournals/gazettenews/2000/CPG_News_0028.pdf
JULY 14TH 2000 WEEK 28 DRUG PATENTING IN CONTEXT Current Patents Gazette is the most rapid competitive intelligence service covering innovation in the pharmaceutical industry.
Applications filed jointly, representing collaborative research, are highlighted, as are sequences of inter- related documents.
In addition there are earlier process cases, which help to confirm the...
|
|
|
http://www.biosis.org/ts/media/cdjournals/gazettenews/2003/CPG_News_0324.pdf
week 0324 13 June 2003 Syntheses of cis-fused 3,3a,8,12b- b]furan derivatives.claimed by Janssen may give clues to potential of follow up compounds of antidepressant lead R-107500.
Schering Corp looks set to gain just over three years’ additional protection for ezetimibe, the hypocholesterolemic azetidinone derivative launched as Zetia/Ezetrol in the US and Germany by the end...
|
|
|
http://www.biosis.org/ts/media/cdjournals/gazettenews/2004/CPG_News_0402.pdf
www.current-patents.com ISSN:1464-3499 The records appearing in this Gazette will be added to DOLPHIN, the Database Of alL PHarmeceutical INventions in the next week.
The other new SPC grant is more complex, since it relies on a patent, EP136011, used in three further SPC applications, one of them veterinary, all relating to contraceptive combinations.
Even this location is not...
|
|
|
PDF cover 0427.qxd
DOLPHIN Current Patents Gazette Patenting in Context News & Highlights from Week 0427 The records appearing in this Gazette will be added to DOLPHIN, the database Of all pharmaceutical inventions in the next week.
This dipivoxil prodrug patenting emerged more than five years after the cases in which adfovir itself and its antiviral use were claimed, EP206459 and EP205826, the...
author: LEmson
|
|
|
New research driving ghrelin forward as an antiobesity target Ghrelin: Pharmaceutical & Therapeutic Opportunities for the
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
|
|
|
Ghrelin: The future of obesity therapeutics?
- - - - BioNews BioWeb Companies Products BioReports - - - - - - Ghrelin: The future of obesity therapeutics?- June 13 2002.
Following the withdrawal of early treatments, the market for anti-obesity pharmaceuticals was reestablished in November 1997, when the FDA approved Abbott's sibutramine (Reductil/Meridia), for use in obesity, and still further in April 1999, when Roche's ...
|
|
|
Obesity Drugs Disappoint
- - - - BioNews BioWeb Companies Products BioReports - - - - - - Biotech Tracker News - Obesity Drugs Disappoint- April 08, 2003, Data presented at the recently concluded 2003 Annual Meeting of the Society for Clinical Pharmacology and Therapeutics verify that long-term treatment with Roche’s (Swiss: ROG) Xenical (orlistat) or sibutramine formulations (such as Abbott...
|
|
|
BioPortfolio Limited
Drugs Approved by the FDA 11.2.1 Profile: Phentermine 11.2.2 Profile: Benzphetamine 11.2.3 Profile: Diethylpropion HCl 11.2.4 Profile: Sibutramine 11.2.5 Profile: Orlistat 11.2.6 Profile: Phendimetrazine 11.3 Shape of the Market Graph 24.
Xenical Share of Individual Countries' Obesity Markets, Sales value for 12 Months to June 2000 Graph 25.
Xenical's Share of...
|
|
|
BioPortfolio Limited
70 Main types of dyslipidemia 73 Hypercholesterolemia 73 Familial hypercholesterolemia 74 Hypertriglyceridemia 74 Familial hypertriglyceridemia 74 Mixed dyslipidemia 75 Epidemiology 75 Drug therapy 78 Statins 79 Fibrates 80 Bile acid sequestrants/inhibitors 81 Nicotinic acid derivatives 82 Fish oil derivatives 82 Market analysis 82 Lipitor (atorvastatin) 84 Zocor (simvastatin) 87...
|
|
|
Haberman Associates: Drug discovery for metabolic diseases
Discovery and development of drugs for metabolic diseases: a case study of the relationships between Big Pharma and biotech companies Allan B.
These include such drugs as rosiglitazone (SmithKline Beecham’s Avandia), and pioglitazone (Lilly’s Actos) for type 2 diabetes and orlistat (Roche’s Xenical) and sibutramine (Knoll AG’s Meridia) for obesity....
author: Allan B. Haberman
|
